Other Biopharmaceuticals

ONO Pharmaceutical Co., Ltd.

4528

OPHLY

Ono Pharmaceutical Co., Ltd. (TSE:4528) shares rose 7.1% to JP¥2,479 after its yearly report, with revenues of JP¥516b meeting forecasts but EPS of JP¥148 falling short by 2.1%. Analysts predict a 12% revenue decline to JP¥454.2b in 2027, with EPS expected to drop 2.8% to JP¥144. The consensus price target remains at JP¥2,221, with a range from JP¥1,750 to JP¥2,950. Overall, analysts see no major changes in business prospects, although revenue growth is expected to lag behind industry averages.

Simplywall

Ono Pharmaceutical

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Ono Pharmaceutical (TSE:4528) reported FY 2026 Q4 revenue of ¥118.7 billion and EPS of ¥1.74, achieving 39.4% earnings growth and a net margin of 13.5%. Despite strong past performance, analysts forecast a 5.7% annual decline in earnings and a 4% drop in revenue over the next three years. The stock trades at a P/E of 16.7x, below peers, with a 3.23% dividend yield, but concerns about future profitability persist. Investors are advised to consider long-term trends and valuations before making decisions.

Ono Pharmaceutical (TSE:4528) Earnings Growth Versus Forecast Declines Tests Bull And Bear Narratives

ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso

Tip Ranks

AstraZeneca

ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso

The MHRA has approved deuruxolitinib, branded as Leqselvi, for treating severe alopecia areata in adults. This new treatment option targets the autoimmune condition that causes hair loss by inhibiting specific enzymes involved in inflammation. The approval follows clinical trials with 1,223 participants, showing significant hair regrowth in those treated with Leqselvi. Approximately 30% of subjects achieved 80% scalp hair coverage after 24 weeks. The medication is available by prescription, with a recommended dosage of 8 mg taken twice daily. The MHRA will continue to monitor its safety and effectiveness.

PharmaTimes

Australian Pharmaceutical Industries Ltd

MHRA approves new treatment for severe alopecia areata

3671

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Softmax Co., Ltd. (Japan)

Curatis and Neupharma sign development agreement for corticorelin in Japan

4886

AnnJi Pharmaceutical Co., Ltd. participated in the 2026 KDA Conference, presenting advancements in AJ201, a potential first-in-class therapy for Spinal and Bulbar Muscular Atrophy (SBMA). The company shared promising Phase 2 clinical results and unveiled the design for a global Phase 3 trial aimed at evaluating AJ201's efficacy and safety. AnnJi also hosted a Patient & Family Forum to engage with the SBMA community and announced the formation of a Patient Advisory Council to optimize trial design. The company remains committed to addressing the unmet needs of SBMA patients.

ONO Pharmaceutical Co., Ltd.(4528.JP)

Analyst Estimates: Here's What Brokers Think Of Ono Pharmaceutical Co., Ltd. (TSE:4528) After Its Yearly Report

Ono Pharmaceutical (TSE:4528) Earnings Growth Versus Forecast Declines Tests Bull And Bear Narratives

ONO Pharmaceutical Nears Key Readout in Lung Cancer Combo Trial With Tagrisso

MHRA approves new treatment for severe alopecia areata

Curatis and Neupharma sign development agreement for corticorelin in Japan

Empowering the SBMA Community: AnnJi Highlights Patient & Family Forum and Shares AJ201 Scientific Advancement at the 2026 KDA Conference